BR112023002301A2 - Anticorpos contra ilt2 e uso dos mesmos - Google Patents

Anticorpos contra ilt2 e uso dos mesmos

Info

Publication number
BR112023002301A2
BR112023002301A2 BR112023002301A BR112023002301A BR112023002301A2 BR 112023002301 A2 BR112023002301 A2 BR 112023002301A2 BR 112023002301 A BR112023002301 A BR 112023002301A BR 112023002301 A BR112023002301 A BR 112023002301A BR 112023002301 A2 BR112023002301 A2 BR 112023002301A2
Authority
BR
Brazil
Prior art keywords
ilt2
antibodies against
methods
antibodies
same
Prior art date
Application number
BR112023002301A
Other languages
English (en)
Portuguese (pt)
Inventor
Anna Fridman-Dror
Avidor Shulman
Haves Ziv Dana
Dror Alishekevitz
Ilana Goldshtein
Ilana Mandel
Motti Hakim
Tehila Ben-Moshe
Tsuri Peretz
Yair Sapir
Original Assignee
Biond Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2020/050889 external-priority patent/WO2021028921A1/en
Application filed by Biond Biologics Ltd filed Critical Biond Biologics Ltd
Publication of BR112023002301A2 publication Critical patent/BR112023002301A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112023002301A 2020-08-12 2021-08-11 Anticorpos contra ilt2 e uso dos mesmos BR112023002301A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IL2020/050889 WO2021028921A1 (en) 2019-08-12 2020-08-12 Antibodies against ilt2 and use thereof
US202163145604P 2021-02-04 2021-02-04
US202163149371P 2021-02-15 2021-02-15
PCT/IB2021/057414 WO2022034524A2 (en) 2020-08-12 2021-08-11 Antibodies against ilt2 and use thereof

Publications (1)

Publication Number Publication Date
BR112023002301A2 true BR112023002301A2 (pt) 2023-10-03

Family

ID=80223922

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002301A BR112023002301A2 (pt) 2020-08-12 2021-08-11 Anticorpos contra ilt2 e uso dos mesmos

Country Status (14)

Country Link
US (1) US12071479B2 (https=)
EP (1) EP4196227A2 (https=)
JP (1) JP2023537396A (https=)
KR (1) KR20230058074A (https=)
CN (1) CN116096756A (https=)
AU (1) AU2021325430A1 (https=)
BR (1) BR112023002301A2 (https=)
CA (1) CA3190634A1 (https=)
CO (1) CO2023002375A2 (https=)
IL (1) IL300588A (https=)
MX (1) MX2023001776A (https=)
TW (1) TW202221035A (https=)
WO (1) WO2022034524A2 (https=)
ZA (1) ZA202302392B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
US20250197491A1 (en) * 2022-03-11 2025-06-19 Macomics Limited Compositions and methods for modulation of macrophage activity
CN116082500B (zh) * 2022-12-09 2023-08-22 珠海重链生物科技有限公司 抗SARS-CoV-2抗体nCoV1和nCoV2及其应用
WO2024207855A1 (zh) * 2023-04-04 2024-10-10 成都优洛生物科技有限公司 抗lilrb1抗体或其抗原结合片段、制备方法和用途
US20250019441A1 (en) 2023-07-11 2025-01-16 Biond Biologics Ltd. Treatment of cancer with anti-ilt2 antibodies
TW202525855A (zh) * 2023-08-31 2025-07-01 美商艾克塞里克斯公司 Ｉｌｔ２結合劑及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
EP3209769B1 (en) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
CA3012055A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
EP3740224A4 (en) * 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
US20210301020A1 (en) 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
EP3902829A2 (en) * 2018-12-26 2021-11-03 Innate Pharma Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
EP4045535A1 (en) 2019-10-14 2022-08-24 Innate Pharma Treatment of cancer with ilt-2 inhibitors
WO2021133036A1 (ko) 2019-12-23 2021-07-01 주식회사 엘지화학 항-lilrb1 항체 및 그의 용도
AU2021265801B2 (en) 2020-05-01 2026-04-02 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof

Also Published As

Publication number Publication date
WO2022034524A3 (en) 2022-04-28
KR20230058074A (ko) 2023-05-02
IL300588A (en) 2023-04-01
EP4196227A2 (en) 2023-06-21
TW202221035A (zh) 2022-06-01
US20220048991A1 (en) 2022-02-17
JP2023537396A (ja) 2023-08-31
ZA202302392B (en) 2025-05-28
CN116096756A (zh) 2023-05-09
AU2021325430A1 (en) 2023-04-20
MX2023001776A (es) 2023-03-10
CO2023002375A2 (es) 2023-03-27
US12071479B2 (en) 2024-08-27
WO2022034524A2 (en) 2022-02-17
CA3190634A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
BR112023002301A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
EA202092518A1 (ru) Композиции и способы лечения рака
MA40913A (fr) Conjugués anticorps-médicament
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
BR112021019107A2 (pt) Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos
MX2021015974A (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
MX2021010453A (es) Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos.
EA202091747A1 (ru) Составы антитела b7-h4
SA523440622B1 (ar) أجسام مضادة
BR112022005465A2 (pt) Conjugados de proteína-macromolécula e métodos de uso dos mesmos
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
MX2023011788A (es) Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
BR112022010361A2 (pt) Anticorpos biespecíficos com cisteínas de intercadeias combinadas alternativamente e usos dos mesmos
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
BR112022020716A2 (pt) Anticorpos anti-tumor associados ao antígeno e usos dos mesmos
EA202092122A1 (ru) Антитела против tip-1 и их применения
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
WO2025081117A3 (en) Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
MX2023014836A (es) Proteínas de unión anti-ctla-4 y métodos de uso de estas.
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение